Bayliss R - Search Results

1

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer.

Sampson J, Ju HM, Zhang N, Yeoh S, Choi J, Bayliss R. Sampson J, et al. Among authors: bayliss r. Cell Death Dis. 2024 Dec 18;15(12):912. doi: 10.1038/s41419-024-07272-7. Cell Death Dis. 2024. PMID: 39695132 Free PMC article.

2

Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.

Sampson J, Richards MW, Choi J, Fry AM, Bayliss R. Sampson J, et al. Among authors: bayliss r. EMBO Rep. 2021 Dec 6;22(12):e53693. doi: 10.15252/embr.202153693. Epub 2021 Oct 18. EMBO Rep. 2021. PMID: 34661367 Free PMC article.

3

EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.

Lucken K, O'Regan L, Choi J, Sampson J, Pashley SL, Bayliss R, Khan S, Fry AM. Lucken K, et al. Among authors: bayliss r. Mol Cancer Res. 2022 Jun 3;20(6):854-866. doi: 10.1158/1541-7786.MCR-21-1010. Mol Cancer Res. 2022. PMID: 35656694 Free PMC article.

4

EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.

Elshatlawy M, Sampson J, Clarke K, Bayliss R. Elshatlawy M, et al. Among authors: bayliss r. Mol Oncol. 2023 Jun;17(6):950-963. doi: 10.1002/1878-0261.13446. Epub 2023 May 15. Mol Oncol. 2023. PMID: 37149843 Free PMC article. Review.

5

ALKing the flames of lung cancer immunosensitivity.

Bayliss R, Sarnowska E, Yeoh S, Sampson J. Bayliss R, et al. Mol Oncol. 2023 Nov;17(11):2218-2220. doi: 10.1002/1878-0261.13533. Epub 2023 Oct 12. Mol Oncol. 2023. PMID: 37795653 Free PMC article.

6

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Bayliss R, et al. Cell Mol Life Sci. 2016 Mar;73(6):1209-24. doi: 10.1007/s00018-015-2117-6. Epub 2016 Jan 11. Cell Mol Life Sci. 2016. PMID: 26755435 Free PMC article. Review.

7

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.

Woo CG, Seo S, Kim SW, Jang SJ, Park KS, Song JY, Lee B, Richards MW, Bayliss R, Lee DH, Choi J. Woo CG, et al. Among authors: bayliss r. Ann Oncol. 2017 Apr 1;28(4):791-797. doi: 10.1093/annonc/mdw693. Ann Oncol. 2017. PMID: 28039177 Free article.

8

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients.

Sabir SR, Yeoh S, Jackson G, Bayliss R. Sabir SR, et al. Among authors: bayliss r. Cancers (Basel). 2017 Sep 5;9(9):118. doi: 10.3390/cancers9090118. Cancers (Basel). 2017. PMID: 28872581 Free PMC article. Review.

9

EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.

O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA, Choi J, Bayliss R, Fry AM. O'Regan L, et al. Among authors: bayliss r. J Cell Sci. 2020 May 11;133(9):jcs241505. doi: 10.1242/jcs.241505. J Cell Sci. 2020. PMID: 32184261 Free PMC article.

10

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC.

Sampson J, Ju HM, Song JY, Fry AM, Bayliss R, Choi J. Sampson J, et al. Among authors: bayliss r. Cancers (Basel). 2022 Feb 2;14(3):779. doi: 10.3390/cancers14030779. Cancers (Basel). 2022. PMID: 35159046 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters